SCHEMBL1367110

SCHEMBL1367110

Cc1ncc(F)c(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19182522 0.96 TDP1 (0.33)
SCHEMBL8268062 0.75
SCHEMBL10620493 0.75
SCHEMBL850260 0.75
SCHEMBL29398110 0.75
SCHEMBL3712628 0.75
SCHEMBL29391663 0.75
SCHEMBL190657 0.75
SCHEMBL4643246 0.71
SCHEMBL13202779 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 US disclosed
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis IDORSIA PHARMACEUTICALS LTD (CH) 2025-07-01 US disclosed
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS DRAIG THERAPEUTICS LTD. (GB) 2025-06-19 US disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 US disclosed
CN-119894872-A Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof 修复治疗公司 2025-04-25 CN disclosed
EP-4526293-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Repare Therapeutics Inc. (CA) 2025-03-26 EP disclosed
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 EP disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 US disclosed
WO-2024217500-A1 ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-24 WO disclosed
EP-2118112-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS Pfizer Inc. (US) 2009-11-18 EP disclosed
US-20080300266-A1 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists ELI LILLY AND COMPANY (US) 2008-12-04 US disclosed
US-20080300266-A1 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists ELI LILLY AND COMPANY (US) 2008-12-04 US disclosed
WO-2008096260-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS PFIZER INC. (US) 2008-08-14 WO disclosed
WO-2008096260-A1 3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS PFIZER INC. (US) 2008-08-14 WO disclosed
CN-101115760-A Pyrrolopyrazoles, potent kinase inhibitors PFIZER (US) 2008-01-30 CN disclosed
US-20080009494-A1 Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2008-01-10 US disclosed
EP-1838718-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS Pfizer, Inc. (US) 2007-10-03 EP disclosed
CN-1976905-A Pyrimidine derivatives and methods of treatment related to their use TAISHO PHARMACEUTICAL CO LTD (JP) 2007-06-06 CN disclosed
WO-2006072831-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER INC. (US) 2006-07-13 WO disclosed